NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Psoriasis Drugs industry
http://www.reportlinker.com/p0197216/Global-Psoriasis-Drugs-industry.html
This report analyzes the worldwide markets for Psoriasis Drugs in US$ Million by the following Drug Administration Routes - Systemic Drugs, and Topical Drugs. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Almirall SA, Astellas Pharma US, Inc., Biogen Idec, Inc., Eisai Co. Ltd., Galderma Laboratories, Isis Pharmaceuticals, Inc., Johnson & Johnson Company, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Stiefel Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Vertex Pharmaceuticals, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
PSORIASIS DRUGS MCP-6324
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Systemic Drugs I-3
Topical Drugs I-4
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW II-1
Psoriasis - A Chronic, Widespread Autoimmune Disease II-1
Table 1: World Psoriasis Prevalence (in Million) in Select
Countries: 2007-2015 (includes corresponding Graph/Chart) II-1
Psoriasis Poses Risk for Cardiovascular Diseases II-2
Quick Facts About Psoriasis Disease II-2
Quick Facts About Psoriasis Treatment II-2
Global Market Outlook II-3
Psoriasis Drugs Overview II-3
Major Marketed Drugs for Psoriasis Treatment as of 2009 II-4
Topical Drugs Overview II-4
Table 2: World Psoriasis Drugs Market - Value Sales of
Select Leading Topical Products in US$ Million for 2008
(includes corresponding Graph/Chart) II-5
Foams and Liquid Formulations Gaining Momentum II-5
JAK3 Inhibitors Spell Promising Future for Topical Drugs II-5
Systemic Drugs Overview II-5
Table 3: World Psoriasis Drugs Market - Value Sales of
Select Leading Conventional Systemic Products in US$ Million
for 2007 (includes corresponding Graph/Chart) II-6
Enbrel - The Market Leader II-6
2. KEY MARKET TRENDS II-7
Market Welcomes New Products, Even As Established Biologic
Makes Exit II-7
Conventional Topical Therapies to Remain Mainstay Treatment II-7
Biologics to Witness Robust Growth, Driven by New Product
Introductions II-8
Interleukin and TNF-Alpha Inhibitors to Drive Biologics Growth II-8
TNF-Alpha Blockers - The Market Leaders II-8
Table 4: World Psoriasis Drugs Market - Value Sales of
Select Leading Biologic Systemic Products in US$ Million for
2008(includes corresponding Graph/Chart) II-9
Interleukin Inhibitors - The Next Big Biologic Class II-9
Non-Prescriptions and Generics Threaten Market Growth II-10
Oral Pipeline Therapies To Take On Biologics II-10
Home Ultraviolet B Therapy to Find Favor with Psoriasis Patients II-10
Paradigm of Psoriasis Treatment II-11
Voclosporin to Edge Out Competitive Products II-11
Apremilast to OUTdo Existing Anti-TNF Products II-11
3. PIPELINE ANALYSIS II-13
The Research Progress in Psoriasis Treatment II-13
Safety Plays Critical Role in Psoriasis Therapy II-13
Major Drug Candidates in Pipeline II-13
Existing and Future Research & Development Approach II-14
Table 5: Psoriasis Drugs Pipeline (2009) - Number of
Pipeline Candidates and Clinical Trials (includes
corresponding Graph/Chart) II-14
Select Psoriasis Pipeline Candidates for Topical Treatment
as of 2009 II-15
Select Psoriasis Pipeline Candidates for Oral Treatment as
of 2009 II-16
Select Psoriasis Pipeline Candidates for Injectable
Treatment as of 2009 II-16
Other Major Psoriasis Pipeline Candidates in Phase II
Clinical Trials as of 2009 II-17
NIAID Researchers Identify Potential New Drug Target II-17
4. ALL ABOUT PSORIASIS II-18
What is Psoriasis? II-18
The History of Psoriasis II-18
The History of Psoriasis Treatment II-18
The Risk Factors of Psoriasis II-19
The Cause(s) of Psoriasis II-19
The Aggravating Factors II-19
The Diagnosis of Psoriasis II-20
The Severity of Psoriasis II-20
The Types of Psoriasis II-21
Plaque Psoriasis II-21
Scalp Psoriasis II-21
Nail Psoriasis II-21
Inverse Psoriasis II-21
Guttate Psoriasis II-22
Pustular Psoriasis II-22
Erythrodermic Psoriasis II-22
Psoriatic Arthritis II-23
Others II-23
The Treatment of Psoriasis II-23
The Three-Step Approach to Treatment II-23
Treatment by Disease Severity II-24
Mild Stage Psoriasis Treatment II-24
Moderate Stage Psoriasis Treatment II-24
Severe Stage Psoriasis Treatment II-24
Treatment by Natural Healing II-25
Other Treatment II-25
5. OVERVIEW OF PSORIASIS TREATMENT II-27
Table 6: Therapeutic Modalities for Psoriasis Treatment in
Percentage by Disease Stage (includes corresponding
Graph/Chart) II-27
Topical Treatment II-28
List of Topical Therapies Available for the Treatment of
Mild-to-Moderate Psoriasis II-28
Select Topical Drugs II-28
Clobex (Clobetasol propionate) II-28
Dovonex (calcipotriene) II-29
Olux-E (Clobetasol propionate) II-29
Taclonex/ Dovobet/ Daivobet (calcipotriene/ betamethasone) II-29
Tazorac (Tazarotene) II-30
Vectical (calcitriol) II-30
Systemic Treatment II-31
Select Conventional Systemic Drugs II-31
Methotrexate II-31
Soriatane (acitretin) II-31
Neoral (cyclosporine) II-32
Tegison (etrentinate) II-32
NSAIDs II-32
Biologic Systemic Therapies II-32
List of Approved Biologic Systemic Therapies for Psoriasis II-33
Select Biologic Drugs II-33
Amevive (alefacept) II-33
Enbrel (etanercept) II-33
Humira (adalimumab) II-34
Remicade (infliximab) II-34
Raptiva (efalizumab) II-35
Stelara (ustekinumab) II-35
Phototherapy II-35
UVB Phototherapy II-36
PUVA Phototherapy II-36
Alternative Treatment II-36
Climatotherapy II-36
6. SELECT CLINICAL TRIALS II-37
Isotechnika's Voclosporin Shows Favorable Results in Phase
III Clinical Trial II-37
Provectus Commences New PH-10 Clinical Trials for Psoriasis II-37
Micromet Initiates First Clinical Study for GM-CSF Human
Antibody MT203 II-37
Welichem Initiates GLP Toxicology Studies for WBI-1001 II-37
Anacor Announces Favorable Phase II Trial Results of AN2728 II-38
Synvista Initiates Phase II Clinical Trial of Topical SYI-2074 II-38
Avontec Announces Positive Results from Phase IIa Clinical
Trial of AVT-02 UE II-38
Revotar Announces Favorable Phase I Trial Results of
Bimosiamose 5% Cream II-38
Manhattan Completes Enrollment in Phase IIa Clinical Trial of
Topical PTH (1-34) II-39
Dermipsor Announces Positive Results from Phase IIb Clinical
Trial of DPS-101 II-39
BioCryst Completes Phase IIa Study, Announces Promising
Results of BCX-4208 II-39
Arana Therapeutics Completes Patient Recruitment in Phase II
Trial of ART621 II-39
Novartis Exploratory Development Study Shows Positive Results
for AEB071 II-40
7. PRODUCT LAUNCHES/ APPROVALS II-41
Eisai Obtains Japanese Approval for HUMIRA® in Psoriasis
Treatment II-41
Janssen-Cilag Launches Stelara® for Plaque Psoriasis II-41
PsoriasisDX Launches Genetic Test for Psoriatic Arthritis II-41
Elorac Launches Zithranol-RR for Plaque Psoriasis II-42
Quinnova Introduces New Treatment for Hyperkeratotic Conditions II-42
Xderma Launches New Ointment for Psoriasis II-43
Promius Pharma Introduces Scytera Foam 2% for Chronic Psoriasis II-43
NeoStrata Launches PSORENT II-43
LEO Pharma to Launch Xamiol® II-43
Glenmark Introduces Dermatology Products II-43
The Kuwait Health Ministry Approves Alalorid for Psoriasis
Treatment II-44
CHMP's Positive Recommendation for Enbrel as Psoriasis
Treatment in Children II-44
8. RECENT INDUSTRY ACTIVITY II-45
Cephalon Acquires Arana Therapeutics II-45
GlaxoSmithKline to Acquire Stiefel Laboratories II-45
PhotoMedex Acquires Photo Therapeutics II-45
PPD Acquires Magen BioSciences II-46
Bristol-Myers Squibb Acquires Medarex II-46
Valeant Pharmaceuticals Acquires Dow Pharmaceutical Sciences II-46
Advitech to Acquire Botaneco Specialty Ingredients II-47
Merck Merges with Schering-Plough II-47
Pfizer Acquires Wyeth II-47
Paladin Labs and Isotechnika Pharma Enter into Partnership II-48
Centocor Ortho Biotech Obtains FDA Approval for Golimumab II-48
Centocor Ortho Biotech Obtains FDA Approval for Stelara™ II-48
Galderma Receives Approval from FDA for Vectical II-49
LEO Pharma Reacquires Product Licensing Rights from Warner
Chilcott II-49
Genentech Withdraws Raptiva from US Market II-49
Prime Pharmaceutical Grants License of Relieva® to Mac Pharma II-50
Dynavax Receives Grant to Support TLR Inhibitors Development
from NIAID II-50
Valeant Pharmaceuticals Takes Over DermaTech II-50
Bayer Takes Over Direvo Biotech II-51
Stiefel Laboratories Acquires Barrier Therapeutics II-51
Biotie Therapies Enters in Agreement to Acquire elbion II-52
Galderma Acquires Collagenex II-52
Abbott Obtains FDA Approval for HUMIRA® in Psoriasis Treatment II-52
LEO Pharma and Warner Chilcott Obtain FDA Approval for
Taclonex Scalp® II-53
Cytos Joins Hands with Pfizer to Develop Vaccines II-53
Karo Bio and Zylus Cadila Enter into Collaboration II-53
Dermipsor Collaborates with Department of Veterans Affairs
and VA Boston Research Institute II-53
GlaxoSmithKline Signs Deal with Dynavax Technologies II-54
RXi Pharmaceuticals Receives Technology License from UMMS II-54
Heilongjiang Tianlong Receives Manufacturing Rights for Four
Medicines II-54
Dara BioSciences Raises Funds for Testing of Drugs II-55
Avidas Pharmaceuticals Acquires Rights from Crown Laboratories II-55
LEO Pharma Sets Up LEO Pharma China II-55
Dr Reddy's Established New Subsidiary in the US II-56
Lupin to Outlicense Psoriasis Drugs II-56
9. FOCUS ON SELECT PLAYERS II-57
Abbott Laboratories (US) II-57
Amgen Inc. (US) II-57
Almirall SA (Spain) II-58
Astellas Pharma US, Inc. (US) II-58
Biogen Idec, Inc. (US) II-59
Eisai Co. Ltd. (Japan) II-59
Galderma Laboratories (Switzerland) II-59
Isis Pharmaceuticals, Inc. (US) II-60
Johnson & Johnson Company (US) II-60
LEO Pharma A/S (Denmark) II-61
Merck & Co., Inc. (US) II-61
Novartis AG (Switzerland) II-62
Stiefel Laboratories, Inc. (US) II-62
Teva Pharmaceutical Industries Ltd. (Israel) II-62
Valeant Pharmaceuticals International (US) II-63
Vertex Pharmaceuticals, Inc. (US) II-63
Wyeth (US) II-64
10. GLOBAL MARKET PERSPECTIVE II-65
Analytics by Geographic Region II-65
Table 7: World Recent Past, Current & Future Analysis for
Psoriasis Drugs by Geographic Region - US, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-65
Table 8: World 10-Year Perspective for Psoriasis Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World Markets for Years 2006,
2009 and 2015 (includes corresponding Graph/Chart) II-66
Analytics by Drug Administration Route II-67
Table 9: World Recent Past, Current & Future Analysis for
Psoriasis Drugs by Drug Administration Route - Systemic Drugs
and Topical Drugs Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-67
Table 10: World 10-Year Perspective for Psoriasis Drugs by
Drug Administration Route - Percentage Breakdown of Dollar
Sales for Systemic Drugs and Topical Drugs Markets for Years
2006, 2009 and 2015 II-67
III. MARKET
1. UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Major Trends III-1
Corticosteroids: Foundation of Mild to Moderate Treatment III-1
Dovonex, Taclonex Remain Standard Topical Treatments III-1
Room for Biologics Penetration As Most Moderate-to- Severe
Cases Remain Untreated for Psoriasis III-2
Enbrel to Lead, Despite Losing Share to Humira III-2
Humira Cuts into Enbrel's Share III-3
Amgen to Redeem 100% North American Rights for Enbrel III-3
J&J's Stelara Unlikely to Take the Market By Storm III-3
FDA Delays Enbrel's Pediatric Psoriasis Indication III-3
Genentech Withdraws Raptiva, Triggers Safety Concerns III-4
Product Launches III-4
Strategic Corporate Developments III-6
Key Players III-13
B.Market Analytics III-19
Table 11: US Recent Past, Current & Future Analysis for
Psoriasis Drugs Market - Annual Sales Figures in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-19
2. JAPAN III-20
A.Market Analysis III-20
Current and Future Analysis III-20
Key Player III-20
B.Market Analytics III-20
Table 12: Japanese Recent Past, Current & Future Analysis
for Psoriasis Drugs Market - Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-20
3. EUROPE III-21
A.Market Analysis III-21
Current and Future Analysis III-21
Product Launches III-21
Strategic Corporate Developments III-21
Key Players III-23
B.Market Analytics III-25
Table 13: European Recent Past, Current & Future Analysis
for Psoriasis Drugs Market - Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-25
4. REST OF WORLD III-26
A.Market Analysis III-26
Current and Future Analysis III-26
Product Launches III-26
Strategic Corporate Developments III-26
B.Market Analytics III-30
Table 14: Rest of World Recent Past, Current & Future
Analysis for Psoriasis Drugs Market - Annual Sales Figures
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-30
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 69 (including Divisions/Subsidiaries - 75)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 46
Canada 3
Japan 1
Europe 14
Germany 2
The United Kingdom 1
Italy 1
Spain 1
Rest of Europe 9
Asia-Pacific (Excluding Japan) 8
Middle-East 3
------------------------------------------
To order this report:
Drug and Medication Industry: Global Psoriasis Drugs industry
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article